Resistance to direct antiviral agents in patients with hepatitis C virus infection.

@article{Sarrazin2010ResistanceTD,
  title={Resistance to direct antiviral agents in patients with hepatitis C virus infection.},
  author={Christoph Sarrazin and Stefan Zeuzem},
  journal={Gastroenterology},
  year={2010},
  volume={138 2},
  pages={447-62}
}
Chronic hepatitis C virus (HCV) infection is one of the major causes of cirrhosis, hepatocellular carcinoma, and liver failure that leads to transplantation. The current standard treatment, a combination of pegylated interferon alfa and ribavirin, eradicates the virus in only about 50% of patients. Directly acting antiviral (DAA) agents, which inhibit HCV replication, are in phase 1, 2, and 3 trials; these include reagents that target the nonstructural (NS)3 protease, the NS5A protein, the RNA… CONTINUE READING
Highly Influential
This paper has highly influenced 23 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 267 extracted citations

HCV-1b intra-subtype variability: Impact on genetic barrier to protease inhibitors.

Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases • 2014
View 10 Excerpts
Highly Influenced

Update on hepatitis C virus resistance to direct-acting antiviral agents.

Antiviral research • 2014
View 12 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 113 references

Accelerated clinical trial design to assess the saftey, tolerability and anti-viral activity of PHX1766, a novel HCV NS4/4A protease inhibitor, in healthy volunteers and chronic hepatitis C patients

M Hotho, J deBruijne, A O’Farrell
Hepatology • 2009

Activity of telaprevir alone or in combination with peginterferon alfa-2a and ribavirin in treatment-naive genotype 2 and 3 hepatitis-C patients: interim results of study C209

GR Foster, C Hezode, JP Bronowicki
J Hepatol 2009;50(Suppl 1):S22 • 2009

Antiviral , pharmacokinetic and safety data for GS9190 , a nonnucleoside HCV NS 5 B polymerase inhibitor in a phase1 trial in HCV genotype 1 infected subjects

L Bavisotto, CC Wang, IM Jacobson
Hepatology • 2009

Antiviral activity , safety and pharamcokinetics of IDX 184 , a livertargeted nucleotide HCV polymerase inhibitor , in patients with chronic hepatitis C

J Lalezari, D Asmuth, A Casiro
2009

Antiviral activity of ANA598, a potent non-nucleoside polymerase inhibitor, in chronic hepatitis C patients

E Lawitz, M Rodriguez-Torres, M DeMicco
J Hepatol 2009;50(Suppl 1):S384 • 2009

Antiviral activity of filibuvir in combination with pegylated interferon alfa-2a and ribavirin for 28 days in treatment-naive patients chronically infected with HCV genotype

I Jacobson, P Pockros, J Lalezari
J Hepatol 2009;50(Suppl • 2009

Antiviral activity, safety and pharamcokinetics of IDX184, a liver-targeted nucleotide HCV polymerase inhibitor, in patients with chronic hepatitis

J Lalezari, D Asmuth, A Casiro
C. Hepatology • 2009

Similar Papers

Loading similar papers…